1. Home
  2. CADL vs LEO Comparison

CADL vs LEO Comparison

Compare CADL & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$4.79

Market Cap

357.4M

Sector

Health Care

ML Signal

HOLD

Logo BNY Mellon Strategic Municipals Inc.

LEO

BNY Mellon Strategic Municipals Inc.

HOLD

Current Price

$6.06

Market Cap

395.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CADL
LEO
Founded
1999
1987
Country
United States
United States
Employees
55
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
357.4M
395.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CADL
LEO
Price
$4.79
$6.06
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$19.71
N/A
AVG Volume (30 Days)
1.2M
137.5K
Earning Date
03-12-2026
01-01-0001
Dividend Yield
N/A
4.01%
EPS Growth
58.62
N/A
EPS
N/A
0.04
Revenue
$125,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$151.75
Revenue Growth
N/A
N/A
52 Week Low
$4.25
$5.67
52 Week High
$7.24
$6.55

Technical Indicators

Market Signals
Indicator
CADL
LEO
Relative Strength Index (RSI) 42.63 29.35
Support Level $4.58 $5.77
Resistance Level $5.42 $6.37
Average True Range (ATR) 0.24 0.07
MACD 0.01 -0.03
Stochastic Oscillator 28.15 15.00

Price Performance

Historical Comparison
CADL
LEO

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About LEO BNY Mellon Strategic Municipals Inc.

BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products include equity and fixed income mutual funds, retail money market funds, government/treasury money market funds, institutional money market funds, and others. The company and its affiliates, as well as others involved in the management, sales, investment activities, business operations, or distribution of the fund, are engaged in businesses and have interests other than those of managing the fund.

Share on Social Networks: